Relevant search

    Leadership Team

    Dr. Tomas Salmonson
    The Chairman of SAB

    Dr. Salmonson served as the chairman of the CHMP, EMA for two consecutive terms from 2012 to 2018. With a high reputation, he has worked in drug regulatory agencies in Sweden and the EMA for more than 30 years. Currently, he is a partner of the Consilium Salmonson & Hemmings, Sweden. He was a member of CHMP representing Sweden from 1999 to 2012. During the last 10 years at the CHMP, he represented the EU at the ICH Steering/Management Committee and the ICH Assembly. Dr. Salmonson obtained his PhD degree (PhD) from Department of Medicine, Uppsala University, Sweden in 1990, and his master's degree (Pharmacy) from Uppsala University, Sweden in 1986. He did research at the University of California, San Francisco in the mid-1980s.

    Dr. Salmonson is productive in different fields such as pharmacokinetics and regulatory science, and has published more than 60 articles and monographs. He won the DIA Outstanding Health Contribution Award in 2016, the Swedish Pharmacist of the Year Award in 2017, and the TOPRA Lifetime Achievement Award in 2018 commending his outstanding contributions to regulatory science and regulatory process.

    Professor Zhang Shuyang
    The member of SAB

    Professor Zhang Shuyang serves as the Dean of Peking Union Medical College Hospital, Deputy Dean of the Peking Union Medical College, Chinese Academy of Medical Sciences, tenured professor of Peking Union Medical College, Chairman of the National Expert Committee on Rare Diseases Diagnosis, Treatment and Guarantee of the National Health Commission, Deputy Director and Secretary General of China Alliance for Rare Diseases, and Director of National Quality Control Center for Rare Diseases. Relying on the national key research & development plan, and focusing on difficult issues such as the diagnosis, evaluation, and prevention of rare diseases, she takes the lead in building the first national rare diseases information management platform, establishing a national three-level collaborative network for diagnosis and treatment of rare diseases, promoting the development of first rare disease catalog, releasing the “Guidelines for Diagnosis & Treatment of Rare Diseases 2019” and “Survey Report on Patients with Rare Diseases”, and exploring the comprehensive diagnosis and treatment model of “multi-omics atlas + multi-disciplinary diagnosis and treatment” for rare diseases in China. With those great efforts, the world’s largest rare diseases diagnosis and treatment collaboration system has been initially established in China.

    Lee S. Simon
    The member of SAB

    Dr. Simon is a senior rheumatologist in the United States. He used to serve as the Division Director of the analgesia, anti-inflammatory and ophthalmic treatment fields, CDER, FDA (2001-2003). Appointed as the director of the American Academy of Rheumatology for two consecutive terms, and taking roles in multiple FDA advisory committees, he has extensive experience in drug development. Dr. Simon is a member of the executive committee involved in the development of celecoxib, a senior consultant for the development of COX-2 inhibitors in Pharmacia/Searle (acquired by Pfizer Inc.), and used to serve as the chairman of the international COX-2 inhibitor research group. He is the chairman of the data and safety monitoring board (DSMB) for numerous clinical trials, including nine randomized controlled trials for rheumatoid arthritis, two trials for IgA nephropathy, and two trials for idiopathic thrombocytopenia. He is a member of DSMB for several systemic lupus erythematosus (SLE) trials and innovative pain therapy trials. Dr. Simon graduated from the Baltimore Medicine School, University of Maryland in 1976, and used to work in the Department of Rheumatology at Harvard Medical School. He is a member of the editorial board of several professional journals, authored more than 110 original publications, reviews and book chapters, and edited several textbooks.

    This website uses cookies to improve website functionality. You may delete or block cookies by accessing your preferences. For more information please read here.